Management Team
Patrick Truesdell
Vice President, Controller & Principal Accounting Officer
Read More about Patrick Truesdell
About Us
Our Story
Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class, oral therapeutics for patients with autoimmune disease. The Company’s mission is to create safer and more effective treatments that address the therapeutic gap in the current treatment paradigm. We are working hard to become the next Immunology Development Powerhouse.
Landos was established as an incredibly productive research engine, with a current portfolio of two novel targets anchoring libraries of immunometabolic modulation pathways, including four potentially first-in-class, once-daily, oral therapies targeting eight indications in the immunology space, including our clinical stage program NX-13 for Ulcerative Colitis and Crohn’s Disease.
Our lead product candidate, NX-13, targets the NLRX1 pathway, a mitochondrial-associated regulatory NOD-like receptor. NX-13 is orally-active and gut-selective, allowing target engagement within the GI tract.
In August 2022, the Company reported positive top-line results from a NX-13 Phase 1b trial, demonstrating a favorable safety and tolerability profile in Ulcerative Colitis patients across a range of once-daily doses. Results also indicate promising early signals of clinical improvement as soon as two weeks in patients’ symptoms and four weeks by endoscopy in exploratory endpoints.
The Company is planning to initiate a Phase 2 proof of concept trial to evaluate the safety, efficacy and optimal dosing of NX-13 in UC patients in the second quarter of 2023.
